TABLE I.
Performance of recent cell filtration platforms. DLD is deterministic lateral displacement; vDLD is virtual DLD; ER is the enrichment ratio. Some flow rate data were converted from other parameters in the corresponding references.
| Technique | Sample | Flow rate (μl/min) | Efficiency | Viability | ER | Remarks | References |
|---|---|---|---|---|---|---|---|
| Dielectrophoretic | Rare bacteria | 5 | 95% | 200 | Buffer required | 55 | |
| MDA-MB cancer | 20 | 70%–80% | Buffer required | 56 | |||
| Immunoselection | H1650 cancer | 167 | 96% | Magnetic | 57 | ||
| CTC | 16–32 | 65% | 98% | 106 | microchip | 58 | |
| Acoustic | Prostate cancer | 100 | 73%–94% | Nonfixed, buffer | 59 | ||
| MCF-7 | 67 | 91% | Buffer required | 60 | |||
| DLD/vDLD | MCF-7 | 2000 | 99% | 115 | DLD | 47 | |
| Polystyrene particles | 4.1 | >97% | vDLD, buffer | 61 | |||
| Inertial | Bacteria in blood | 200 | 4 | Two stages | 34 | ||
| MCF-7 | 4000 | <27% | 86% | 104 | Vortex, 8 channels | 48 | |
| Leukocyte | 800 | >80% | 98% | Trapezoid spiral | 49 | ||
| Malaria infected RBCs | 5 | >80% | 2 | Deformability | 50 | ||
| MCF-7 | 5 | 99% | Sheath flow | 52 | |||
| MCF-7/modMCF-7 | 42 | 92% | 5.35 | Deformability | 51 | ||
| Neuroblastoma and glioma | 2500 | >80% | 90% | Dean flow, spiral | 21 | ||
| LNCaP, HPET | 225 | >99.5% | 83% | 3 | Single stage | This work | |
| Non-inertial | MV3-melanoma | 0.33 | 98.7% | Sheath flow | 62 |